539268 Stock Overview
A contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Syngene International Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹869.40 |
| 52 Week High | ₹945.75 |
| 52 Week Low | ₹608.00 |
| Beta | 0.58 |
| 11 Month Change | -0.56% |
| 3 Month Change | 1.81% |
| 1 Year Change | 16.60% |
| 33 Year Change | 47.32% |
| 5 Year Change | 174.09% |
| Change since IPO | 460.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 539268 | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 0.9% | 3.2% | 0.5% |
| 1Y | 16.6% | 48.3% | 27.5% |
Return vs Industry: 539268 underperformed the Indian Life Sciences industry which returned 48.3% over the past year.
Return vs Market: 539268 underperformed the Indian Market which returned 27.5% over the past year.
Price Volatility
| 539268 volatility | |
|---|---|
| 539268 Average Weekly Movement | 4.0% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 539268 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 539268's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 6,510 | Jonathan Hunt | www.syngeneintl.com |
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services.
Syngene International Limited Fundamentals Summary
| 539268 fundamental statistics | |
|---|---|
| Market cap | ₹348.83b |
| Earnings (TTM) | ₹4.82b |
| Revenue (TTM) | ₹34.51b |
72.4x
P/E Ratio10.1x
P/S RatioIs 539268 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 539268 income statement (TTM) | |
|---|---|
| Revenue | ₹34.51b |
| Cost of Revenue | ₹11.19b |
| Gross Profit | ₹23.32b |
| Other Expenses | ₹18.51b |
| Earnings | ₹4.82b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 12.01 |
| Gross Margin | 67.58% |
| Net Profit Margin | 13.96% |
| Debt/Equity Ratio | 3.6% |
How did 539268 perform over the long term?
See historical performance and comparison